A nested cohort 5-year Canadian surveillance of Gram-negative antimicrobial resistance for optimized antimicrobial therapy

Author:

Blondeau Joseph,Charles Marthe Kenny,Loo Vivian,Adam Heather,Gonzalez Del Vecchio Marcela,Ghakis Christiane,O’Callaghan Emma,El Ali Radwan

Abstract

AbstractWe analyzed 5 years (2016–2020) of nested Canadian data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) to identify pathogen predominance and antimicrobial resistance (AMR) patterns of adult Gram-negative infections in Canadian health care and to complement other public surveillance programs and studies in Canada. A total of 6853 isolates were analyzed from medical (44%), surgical (18%), intensive care (22%) and emergency units (15%) and from respiratory tract (36%), intra-abdominal (25%), urinary tract (24%) and bloodstream (15%) infections. Overall, E. coli (36%), P. aeruginosa (18%) and K. pneumoniae (12%) were the most frequent isolates and P. aeruginosa was the most common respiratory pathogen. 18% of Enterobacterales species were ESBL positive. Collective susceptibility profiles showed that P. aeruginosa isolates were highly susceptible (> 95%) to ceftolozane/tazobactam and colistin, though markedly less susceptible (58–74%) to other antimicrobials tested. Multi-drug resistance (MDR) was present in 10% of P. aeruginosa isolates and was more frequent in those from respiratory infections and from ICU than non-ICU locations. Of P. aeruginosa isolates that were resistant to combinations of ceftazidime, piperacillin/tazobactam and meropenem, 73–96% were susceptible to ceftolozane/tazobactam over the period of the study. These national data can now be combined with clinical prediction rules and genomic data to enable expert antimicrobial stewardship applications and guide treatment policies to optimize adult patient care.

Funder

Merck Canada

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Reference53 articles.

1. Lonsdale, D. O. & Lipman, J. Antimicrobial resistance: We must pursue a collaborative, global approach and use a “One Health” approach. Antibiotics 8(4), 66. https://doi.org/10.3390/antibiotics8040237 (2019).

2. Spaulding, C. N., Klein, R. D., Schreiber, H. L., Janetka, J. W. & Hultgren, S. J. Precision antimicrobial therapeutics: The path of least resistance?. NPJ Biofilms Microbiomes 4, 4. https://doi.org/10.1038/s41522-018-0048-3 (2018).

3. Public Health Agency of Canada. Progress Report on the 2015 Action Plan on Antimicrobial Resistance and Use. 2018. https://www.canada.ca/content/dam/phac-aspc/documents/services/publications/drugs-health-products/progress-report-2015-federal-action-plan-antimicrobial-resistance-use/pub-eng.pdf

4. Pan Canadian Public Health Network. Antimicrobial Stewardship. The Communicable and Infectious Disease Steering Committee Task Group on Antimicrobial Use Stewardship. Final Report to the Public Health Network Council, 2016. 2016. http://www.phn-rsp.ca/pubs/anstew-gestan/pdf/pub-eng.pdf

5. Public Health Agency of Canada. Tackling Antimicrobial Resistance and Antimicrobial Use. A Pan-Canadian Framework for Action. Public Health Agency of Canada. https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/tackling-antimicrobial-resistance-use-pan-canadian-framework-action.html

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3